Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Correction to: BMC Cancer

https://doi.org/10.1186/s12885-019-5687-0

Following publication of the original article [1], the authors reported the following errors in the article.

• 1) In Table 2, the layout has been updated. The corrected Table 2 is supplied below:

• 2) The legend for Fig. 3 has been adapted for clearer readability. The updated legend is as follows:

• 3) The competing interests statement has been updated below.

Table 2 Progression-free survival by HER2 expression subgroups

Fig. 3

Kaplan–Meier curve of PFS in subgroups defined by the presence/absence of negatively impacting biomarkers.*

*Biomarkers were considered negatively prognostic of response to HER2-targeted treatment based on their association with a numerical decrease in PFS. Specifically, these included expression of mutated PIK3CA, low HER2 mRNA level (≤median), and focal HER2 distribution. Patients without negative markers were those with nonmutated PIK3CA, high HER2 mRNA levels (>median), and non-focal (i.e., heterogeneous or homogenous) distribution of HER2. Patients with negative markers were those with mutated PIK3CA, low HER2 mRNA levels (≤median), and focal HER2 distribution. HER2 human epidermal growth factor receptor 2, PIK3CA phosphoinositide 3-kinase catalytic subunit alpha, PFS progression-free survival, T-DM1 trastuzumab emtansine